Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/28949


Angiogenesis Inhibitors 2001 - State-of-the-Science and Strategic Opportunities


Description: Anti-angiogenic agents are believed to hold great promise in the fight against cancer. With more than 20 of such agents in different stages of clinical development, angiogenesis inhibitors are considered one of the most exciting areas of cancer research today. Recent setbacks in the clinical development of several matrix metalloproteinase inhibiting compounds and fast progress in the area of signal transduction suggest that targeting tyrosin kinase and Vegf signaling pathways seems to be the most promising technological venue for bringing a product to the market soon. Pharmacia, Pfizer, Bristol-Myers Squibb, AstraZeneca, Novartis, American Home Products and Genentech have all recognized this viable research venue and have initiated research activities in the field either through in-licensing or through acquisitions. With so much research directed and money thrown at the field of angiogenesis inhibition we believe that a viable market will be created by 2006 with the first product entering the market as early as 2004. Angiogenesis Inhibitors 2001 describes the different technological strategies employed to develop anti-angiogenic agents as cancer therapeutics and assesses the potential of drugs currently in clinical trials. Angiogenesis Inhibitors 2001 edition features updated analysis of biopharmaceutical leaders in angiogenesis medicine, their technologies and their product pipelines. It also envisions different market development scenarios and provide forecasts for the year 2006.


Contents:

I. Executive Briefing
II. State of The Science
A. Introduction
B. Process of Angiogenesis

1. Physiological and Pathological Angiogenesis
2. The Angiogenic Sequence
3. Angiogenic Growth Factors
C. Angiogenesis and Cancer

1 The Role of Angiogenesis in Cancer Progression
2. Angiogenesis Inhibitors in Cancer Research
3. Angiogenesis Inhibitors Versus Standard Chemotherapy

III. Technological Strategies for Angiogenesis Inhibition
A. Inhibiting VEGF Signaling Pathway

1. Role of VEGF in Angiogenesis
2. Inhibiting Secretion of Endogenous Tumor VEGF
3. Neutralizing VEGF in the Microcirculation
4. Preventing VEGF Binding and Subsequent Signal
Transduction
B. Use of Naturally Occuring Angiogenesis Inhibitors
C. Direct Inhibition of Endothelial Cells
D. Blocking Extracellular Matrix Breakdown
E. Inhibiting Endothelial Cell Adhesion Receptors
F. Inhibiting Cyclooxygenase-2 (COX-2 Inhibitors)
G. Vascular Targeting Agents
IV. Leading Companies and Their Products
A. Aeterna
B. American Home Products - Genetics Institute
C. AstraZeneca
D. Bristol-Myers Squibb
E. British Biotech
F. Celgene
G. Collagenex
H. Cytran
I. Entremed
J. Genentech
K. Oxigene
L. Magainin
M. Merck Kgaa
N. National Cancer Institute
O. Novartis
P. TAP
Q. Pharmacia - Sugen
R. Pfizer - Agouron
S. Other Companies with Products in Early Development

1. OSI Pharmaceuticals
2. Medimmune
3. Regeneron
4. Ribozyme
5. ImClone
6. Genzyme
7. Peregrine

V. Future Perspectives
A. Potential Market
B. Angiogenesis Inhibitors Near Commercialization
C. Angiogenesis Inhibitors on the Path to Registration
VI. Strategic Discussion
A. Facts & Hype
B. Clinical Strategies for the Development of Angiogenesis Inhibitors
C. Market Development Scenarios

1. Indication Based Development
2. Angiogenesis Inhibitors Cocktails
3. Combination Therapies
4. Fingerprinting Tumors for Angiogenic Signature
5. Blockbuster Drugs
D. Winning Strategies
E. The Shape of the Market in 2006




Ordering: Order Online - visit http://www.researchandmarkets.com/reports/28949

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 06/10/2008 23:55:40
Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com


Order information

Please verify that the product information is correct and select the format you require.

Product Name:
Angiogenesis Inhibitors 2001 - State-of-the-Science and Strategic Opportunities
Web Address:
http://www.researchandmarkets.com/reports/28949
Office Code:
OCHJKKIOOUV

Report formats

Please enter the quantity of the report format you require.

Format Quantity Price
Hard Copy €1,017.00 + EUR€ 50.00 Shipping/Handling *
Electronic €519.00
Electronic - Site License €1,926.00

* Shipping/Handling is only charged once per order.


Contact information

Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World

Research and Markets Page 2 of 2
Printed 06/10/2008 23:55:40

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder Name:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.


If you have a Marketing Code please enter it below:

Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp



Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World